Allt inom Corporate Information
Nanexa doses the last patients with 30 mg liraglutide in the NEX-22-01 study
Nanexa announces that all patients have now been included in the fourth and final dose cohort in the Phase I study of NEX-22, a one-month formulation of liraglutide.
Nanexa doses first patient in the 30 mg dose group in the Phase I study with NEX-22
Nanexa AB announces today that the first patient has been dosed in the 30 mg dose group in the ongoing Phase I study with NEX-22, the company’s one-month formulation of liraglutide.